Johnson Craig A 4

What Happened
Craig A. Johnson, a director of Aurinia Pharmaceuticals (AUPH), received a derivative award on 2026-06-04 consisting of 23,931 shares (reported as a $0.00 acquisition on the Form 4). The filing lists this as an award/grant (transaction code A). The Form 4 does not disclose an exercise/strike price or an immediate cash value for the grant.

Key Details

• Transaction date: 2026-06-04; Form 4 filed 2026-06-08 (timely filing).
• Type: Grant / award (derivative) — 23,931 shares reported at $0.00.
• Shares owned after transaction: Not disclosed in this filing.
• Footnote: The options shall vest one year from the date of grant. (F1)
• No immediate sale or exercise reported in this filing.

Context
This was a compensatory derivative grant to a director, not a market purchase or sale. Because the Form 4 lists $0.00 and does not show an exercise price, the report doesn't indicate the award's intrinsic or potential value — vesting and any exercise terms will determine future value. Director grants are common as part of compensation and do not, by themselves, indicate the director's intent to buy or sell shares.